Windlas Biotech Limited
NSE: WINDLAS · Pharmaceuticals · sector
₹882.50NSE close 2026-10-26
Key numbers
Market cap₹1,821 cr
Price₹882.50
52w high / low₹1,182 / ₹697
P/E27.9xSector median 27.9x
P/B3.1xSector median 2.9x
Book value₹281.5
Dividend yield0.66%Sector median 0.48%
ROE12.2%Sector median 11.7%
ROCE15.1%Sector median 12.3%
OPM11.1%Sector median 14.0%
Debt / equity0.05xSector median 0.16x
EV/EBITDA15.1xSector median 18.6x
Interest cover17.0x
Current ratio1.95x
Sales growth 3y+20.8%Sector median +9.6%
Profit growth 3y+15.9%Sector median +13.3%
PEG1.64x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹270 cr vs borrowings ₹30 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 17.0x in the last 12 months.
- Promoter holding rose by 1.32 percentage points in a year, to 63.31% (2026-09-30).
- Operating cash flow was below net profit in 1 of the last 5 years (FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 27% of net profit in the last 12 months.
- Debtor days went from 79 (FY24) to 92 (FY26).
- Dividend paid in 4 of the last 5 financial years.
- Price ₹882.50 on 2026-10-26: -25.3% from the 52-week high, +26.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,142.45 · low ₹705.75
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 187 | 195 | 203 | 210 | 222 | 233 | 238 | 248 |
| EBITDA | 23 | 25 | 26 | 27 | 29 | 24 | 25 | 27 |
| OPM % | 12.3% | 12.6% | 12.6% | 12.6% | 12.8% | 10.5% | 10.6% | 10.8% |
| Other income | 5 | 4 | 5 | 5 | 4 | 5 | 4 | 5 |
| Net profit | 16 | 15 | 16 | 18 | 18 | 15 | 16 | 18 |
| EPS (₹) | 7.49 | 7.29 | 7.77 | 8.43 | 8.48 | 7.09 | 7.60 | 8.46 |
| Revenue YoY | +18.9% | +19.5% | +17.7% | +18.1% | ||||
| Profit YoY | +13.7% | -1.8% | -1.7% | -0.1% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 466 | 513 | 631 | 760 | 904 | 942 |
| EBITDA | 53 | 60 | 78 | 94 | 105 | 105 |
| Net profit | 39 | 43 | 58 | 61 | 66 | 66 |
| EPS (₹) | 18.81 | 19.71 | 27.95 | 29.03 | 31.59 | 31.63 |
| Revenue growth | +10.1% | +23.0% | +20.4% | +19.0% | +18.5% | |
| Profit growth | +10.6% | +36.4% | +4.3% | +9.5% | +2.5% | |
| Dividend / share (₹) | – | 3.50 | 4.00 | 5.50 | 5.80 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +20.8% | – | +18.5% |
| Net profit | +15.9% | – | +2.4% |
| EPS | +17.0% | – | – |
| Share price | – | -6.3% (2y) | -7.4% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 403 | 450 | 506 | 581 |
| Borrowings | – | 0 | 0 | 27 | 30 |
| Cash & equivalents | – | 132 | 204 | 239 | 270 |
| Total assets | – | 529 | 626 | 760 | 907 |
| Fixed assets | – | 103 | 169 | 195 | 187 |
| Capital work in progress | – | 14 | 6 | 3 | 56 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 117 | 136 | 167 | 227 |
| Inventory | – | 75 | 62 | 81 | 62 |
| Payables | – | 87 | 131 | 167 | 238 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 9 | 61 | 109 | 68 | 105 |
| Cash from investing | -154 | -14 | -92 | -74 | -92 |
| Cash from financing | 130 | -44 | -15 | 1 | -13 |
| Capex | 15 | 71 | 38 | 52 | 68 |
| Free cash flow | -6 | -10 | 71 | 16 | 37 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 10.6% | 12.9% | 12.0% | 11.4% |
| ROCE % | – | 14.3% | 17.3% | 15.7% | 15.0% |
| Debtor days | – | 83 | 79 | 80 | 92 |
| Inventory days | – | 84 | 57 | 63 | 40 |
| Payable days | – | 98 | 121 | 129 | 156 |
| Cash conversion cycle (days) | – | 69 | 15 | 14 | -24 |
| Working capital days | – | 166 | 150 | 132 | 124 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 63.31% |
| FIIs | 2.08% |
| DIIs | 7.24% |
| of which Mutual funds | 3.10% |
| Public (non-institutions) | 27.36% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | May 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 62.34% | 62.34% | 61.99% | 61.99% | 61.90% | 63.31% | 63.31% | 63.31% |
| Promoter group | % |
|---|---|
| AKW WBL Family Private Trust (through its Trustees Ashok Vimla Trusteeship Services Private Limited) | 40.61% |
| Ashok Kumar Windlass | 21.32% |
| Vimla Windlasss | 1.38% |
| Hitesh Windlass | 0.00% |
| Manoj Kumar Windlass | 0.00% |
| Payal Windlass | 0.00% |
| Prachi Jain Windlass | 0.00% |
| Vani Windlass Shukla | 0.00% |
| Rhiditya Windlass | 0.00% |
| Atharv Windlass | 0.00% |
| Abha Jain | 0.00% |
| Ankur Jain | 0.00% |
| Richa Mittal | 0.00% |
| Ayann Windlass | 0.00% |
| Araddhya Windlass | 0.00% |
| Public holders above 1% | % |
|---|---|
| Icici Prudential Healthcare Fund | 1.73% |
| Mncl Capital Compounder Fund 2 | 1.70% |
| Ajay Kumar Aggarwal | 1.21% |
| Perpetuity Health To Wealth (H2w) Rising Fund | 1.11% |
48,732 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| WINDLAS | ₹1,821 cr | 27.9x | 3.1x | 12.2% | 15.1% | 11.1% | +20.8% | 0.66% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-16 | Dividend | Dividend - Rs 6.30 Per Share |
| 2026-04-24 | Buyback | Buy Back |
| 2025-07-21 | Dividend | Dividend - Rs 5.80 Per Share |
| 2024-09-17 | Dividend | Dividend - Rs 5.50 Per Share |
| 2024-09-17 | Other | Annual General Meeting |
| 2023-09-05 | Dividend | Annual General Meeting/Dividend - Rs 4 Per Share |
| 2022-09-09 | Dividend | Annual General Meeting/Dividend - Rs 3.50 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | WINDLAS |
| BSE code | 543329 |
| ISIN | INE0H5O01029 |
| Face value | ₹5.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.